Xencor Inc
XNCR
Delayed Nasdaq - 09/25 10:00:00 pm
22.47USD
+2.84%

Xencor : State of Wisconsin Investment Board Takes $612,000 Position in Xencor, Inc. (XNCR)

Envoyer par e-mail
09/14/2017 | 10:44 am

State of Wisconsin Investment Board acquired a new stake in Xencor, Inc. (NASDAQ:XNCR) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 29,000 shares of the biopharmaceutical companys stock, valued at approximately $612,000. State of Wisconsin Investment Board owned 0.06% of Xencor as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Equitec Specialists LLC acquired a new position in Xencor in the 2nd quarter valued at approximately $116,000. Airain ltd acquired a new position in Xencor in the 1st quarter valued at approximately $213,000. Clinton Group Inc. increased its stake in Xencor by 4.6% in the 1st quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical companys stock valued at $382,000 after buying an additional 700 shares during the period. Bank of America Corp DE increased its stake in Xencor by 144.4% in the 1st quarter. Bank of America Corp DE now owns 16,199 shares of the biopharmaceutical companys stock valued at $387,000 after buying an additional 9,572 shares during the period. Finally, American International Group Inc. increased its stake in Xencor by 18.0% in the 1st quarter. American International Group Inc. now owns 21,824 shares of the biopharmaceutical companys stock valued at $522,000 after buying an additional 3,332 shares during the period. Hedge funds and other institutional investors own 76.92% of the companys stock.

Xencor, Inc. (NASDAQ XNCR) opened at 22.80 on Tuesday. Xencor, Inc. has a 52 week low of $18.45 and a 52 week high of $29.38. The firms market cap is $1.07 billion. The stocks 50 day moving average is $21.79 and its 200 day moving average is $22.70.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks consensus estimate of ($0.25) by $0.10. The business had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. Equities research analysts expect that Xencor, Inc. will post ($1.17) EPS for the current year.

In other Xencor news, major shareholder John S. Stafford III acquired 41,016 shares of the businesss stock in a transaction dated Tuesday, August 22nd. The shares were acquired at an average price of $19.69 per share, with a total value of $807,605.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder John S. Stafford III acquired 1,500 shares of the businesss stock in a transaction dated Friday, June 16th. The stock was acquired at an average cost of $19.67 per share, for a total transaction of $29,505.00. The disclosure for this purchase can be found here. In the last three months, insiders bought 223,051 shares of company stock worth $4,536,061. 4.14% of the stock is currently owned by insiders.

XNCR has been the topic of several research reports. Wedbush reiterated an outperform rating and issued a $29.00 price objective on shares of Xencor in a research note on Tuesday, June 6th. Zacks Investment Research lowered shares of Xencor from a hold rating to a sell rating in a research note on Friday, August 11th. BidaskClub lowered shares of Xencor from a hold rating to a sell rating in a research note on Monday, August 14th. ValuEngine upgraded shares of Xencor from a sell rating to a hold rating in a research note on Friday, September 1st. Finally, Canaccord Genuity reiterated a buy rating and issued a $36.00 price objective on shares of Xencor in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the companys stock. The stock currently has a consensus rating of Hold and an average price target of $29.33.

(c) 2017 ITP Business Publishing Ltd. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Acquiremedia 2017
Envoyer par e-mail